Programs

Focusing on significant areas of unmet medical need

Vesigen’s therapeutic programs using ARMMs technology have the potential to provide novel treatments for patients in a wide range of disease areas.

Disease areas of focus

Vesigen is pursuing multiple programs through both in-house development and collaborations, currently focusing on the following disease areas:

Neurology

Delivery to the central nervous system, particularly into neurons, has proven extremely challenging for existing technologies. Vesigen is exploring ARMMs-based therapeutic programs targeting neurological diseases for which there are no available treatments.

Ocular

Current technologies for systemic and topical delivery of ophthalmologic therapies are inefficient and often limited by tolerability issues, and intravitreal injections are invasive and require direct physician involvement. Vesigen is developing therapeutic programs using ARMMs technology to overcome current limitations and improve options for patients.

Oncology

There are numerous validated intracellular targets in oncology that are ill-suited to intervention with current modalities. Vesigen is pursuing programs that will deliver highly specific, novel therapeutic agents directly to the cytoplasm of tumor cells.

ARMMs will allow us to develop targeted therapeutics that realize the promise of genomic medicine and modalities such as shRNA, mRNA and protein replacement, and gene editing, with the potential to transform patient care and treatment.

Dr. Quan Lu
Co-Founder, Vesigen Therapeutics

Explore a partnership

Interested in partnering with Vesigen?